Yuhang Zhao Biography and Net Worth

Director of OncoSec Medical

Dr. Yuhang Zhao, a graduate from Peking University, received her Doctorate in Molecular Biology from Rockefeller University and her MBA in Finance from NYU Stern Business School.
Dr. Zhao was most recently a member of the Bayer Global Leadership Circle. She established one of Bayer’s four Global Clinical Development sites, located in Beijing, China in 2009. She then became Head of Global Strategy for Bayer Consumer Health, reporting to the President. Prior to her positions in the pharmaceutical industry, Dr. Zhao held positions as a stock analyst at PaineWebber and was a management consultant specializing in strategies for life science companies. Dr. Zhao currently serves on the board of R2 Technologies and is a senior adviser to China Grand Enterprises.

What is Yuhang Zhao's net worth?: The estimated net worth of Yuhang Zhao is at least $0.00 as of August 23rd, 2021. Dr. Zhao owns 8,000 shares of OncoSec Medical stock worth more than $0 as of April 19th. This net worth evaluation does not reflect any other investments that Dr. Zhao may own. Learn More about Yuhang Zhao's net worth.
How do I contact Yuhang Zhao?: The corporate mailing address for Dr. Zhao and other OncoSec Medical executives is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. OncoSec Medical can also be reached via phone at (855) 662-6732 and via email at [email protected]. Learn More on Yuhang Zhao's contact information.
Has Yuhang Zhao been buying or selling shares of OncoSec Medical?: Yuhang Zhao has not been actively trading shares of OncoSec Medical during the last quarter. Most recently, on Monday, August 23rd, Yuhang Zhao bought 4,000 shares of OncoSec Medical stock. The stock was acquired at an average cost of $1.88 per share, with a total value of $7,520.00. Following the completion of the transaction, the director now directly owns 8,000 shares of the company's stock, valued at $15,040. Learn More on Yuhang Zhao's trading history.
Who are OncoSec Medical's active insiders?: OncoSec Medical's insider roster includes Robert DelAversano (VP), Brian Leuthner (CEO), Daniel O'Connor (CEO), and Yuhang Zhao (Director). Learn More on OncoSec Medical's active insiders.

Yuhang Zhao Insider Trading History at OncoSec Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/23/2021	Buy	4,000	$1.88	$7,520.00	8,000
8/20/2021	Buy	8,000	$1.94	$15,520.00

Yuhang Zhao Buying and Selling Activity at OncoSec Medical

OncoSec Medical Company Overview

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Today's Range

Now: N/A

50 Day Range

MA: $0.52

$0.20

$0.94

2 Week Range

Now: N/A

Volume

52,491,000 shs

Average Volume

2,219,449 shs

Market Capitalization

$1.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

The A.I. story nobody is telling you (Read ASAP)

From TradeSmith | Ad

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.